Matches in SemOpenAlex for { <https://semopenalex.org/work/W2070295008> ?p ?o ?g. }
Showing items 1 to 51 of
51
with 100 items per page.
- W2070295008 abstract "Bisphosphonates are the standard of care for preventing skeletal morbidity and treating hypercalcemia of malignancy in patients with bone metastases. Zoledronic acid (intravenous; 4 mg monthly) is approved to prevent skeletal-related events in patients with bone metastases from several tumor types, and can improve survival in some subsets of patients with skeletal metastases and high baseline bone turnover. In the adjuvant setting, bisphosphonates have shown clinical efficacy for preventing cancer treatment-induced bone loss and promise for reducing disease recurrence. For example, early studies of clodronate showed the potential for bisphosphonates to prevent bone metastases and prolong survival, but results with clodronate have been inconsistent. Recently, the more active bisphosphonate zoledronic acid (4 mg every 6 months) prevented bone loss and significantly reduced the risk of disease-free survival events by 36% (P = 0.01) compared with adjuvant endocrine therapy alone in a large phase III trial (n = 1,803) in premenopausal women with early breast cancer [1]. Notably, these benefits were not limited to bone because the addition of zoledronic acid reduced disease recurrence at all sites. This fuels the See-and-Soil hypothesis about dormant tumor (stem) cells in early disease, and hints towards a potential impact of bisphosphonate treatment on the bone marrow microenvironment. These results of twice-yearly zoledronic acid have been confirmed indirectly in bone-protection trials in postmenopausal patients [2]. In addition, several ongoing trials (involving more than 20,000 patients altogether) are evaluating the efficacy of bisphosphonates for the prevention of metastases in breast, prostate, and lung cancers, and multiple myeloma. Results from these studies are likely to expand the role of bisphosphonates, particularly zoledronic acid, in the adjuvant therapy setting, and help us in elucidating the underlying biology as well as resolving open clinical questions." @default.
- W2070295008 created "2016-06-24" @default.
- W2070295008 creator A5001256203 @default.
- W2070295008 date "2009-06-01" @default.
- W2070295008 modified "2023-10-16" @default.
- W2070295008 title "Bisphosphonates in the adjuvant treatment of early breast cancer" @default.
- W2070295008 cites W2148096512 @default.
- W2070295008 doi "https://doi.org/10.1186/bcr2278" @default.
- W2070295008 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4284881" @default.
- W2070295008 hasPublicationYear "2009" @default.
- W2070295008 type Work @default.
- W2070295008 sameAs 2070295008 @default.
- W2070295008 citedByCount "1" @default.
- W2070295008 crossrefType "journal-article" @default.
- W2070295008 hasAuthorship W2070295008A5001256203 @default.
- W2070295008 hasBestOaLocation W20702950081 @default.
- W2070295008 hasConcept C121608353 @default.
- W2070295008 hasConcept C126322002 @default.
- W2070295008 hasConcept C143998085 @default.
- W2070295008 hasConcept C2777863537 @default.
- W2070295008 hasConcept C2780140570 @default.
- W2070295008 hasConcept C530470458 @default.
- W2070295008 hasConcept C71924100 @default.
- W2070295008 hasConceptScore W2070295008C121608353 @default.
- W2070295008 hasConceptScore W2070295008C126322002 @default.
- W2070295008 hasConceptScore W2070295008C143998085 @default.
- W2070295008 hasConceptScore W2070295008C2777863537 @default.
- W2070295008 hasConceptScore W2070295008C2780140570 @default.
- W2070295008 hasConceptScore W2070295008C530470458 @default.
- W2070295008 hasConceptScore W2070295008C71924100 @default.
- W2070295008 hasIssue "S1" @default.
- W2070295008 hasLocation W20702950081 @default.
- W2070295008 hasLocation W20702950082 @default.
- W2070295008 hasLocation W20702950083 @default.
- W2070295008 hasOpenAccess W2070295008 @default.
- W2070295008 hasPrimaryLocation W20702950081 @default.
- W2070295008 hasRelatedWork W1504984147 @default.
- W2070295008 hasRelatedWork W2004631926 @default.
- W2070295008 hasRelatedWork W2052163941 @default.
- W2070295008 hasRelatedWork W2092731544 @default.
- W2070295008 hasRelatedWork W2100720486 @default.
- W2070295008 hasRelatedWork W2125052450 @default.
- W2070295008 hasRelatedWork W2163676795 @default.
- W2070295008 hasRelatedWork W2503964141 @default.
- W2070295008 hasRelatedWork W2982480961 @default.
- W2070295008 hasRelatedWork W4248497383 @default.
- W2070295008 hasVolume "11" @default.
- W2070295008 isParatext "false" @default.
- W2070295008 isRetracted "false" @default.
- W2070295008 magId "2070295008" @default.
- W2070295008 workType "article" @default.